Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

In the last three months, 4 analysts have published ratings on BioNTech (NASDAQ:BNTX), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary ...

BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...

All target abbreviations are compiled in an abbreviation directory at the end of this press release. All numbers in this press release have been rounded.

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

BioNTech SE earnings at a glance (GAAP ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...

Biopharmaceutical company BioNTech SE (NASDAQ:BNTX) reported fourth-quarter and full-year 2024 earnings on Monday, March 10, that topped analysts' consensus expectations. It reported revenue of 1. ...